NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
Open Access
- 10 May 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (30) , 49548-49563
Abstract
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaKeywords
This publication has 63 references indexed in Scilit:
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaBlood, 2010
- Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blastsBlood, 2009
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005